These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 24216259

  • 1. Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
    Adema AY, de Borst MH, Ter Wee PM, Vervloet MG, NIGRAM Consortium.
    J Ren Nutr; 2014 May; 24(3):143-50. PubMed ID: 24216259
    [Abstract] [Full Text] [Related]

  • 2. Hyperphosphatemia and phosphate binders: effectiveness and safety.
    Kalaitzidis RG, Elisaf MS.
    Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA, Stephens BW.
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C, Roe K, Lehman E, Verma N.
    Nephron Clin Pract; 2013 Mar; 123(1-2):61-6. PubMed ID: 23774446
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The challenge of controlling phosphorus in chronic kidney disease.
    Cannata-Andía JB, Martin KJ.
    Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
    Hanba Y, Masumoto A, Moribata M, Shigemathu T.
    Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
    [Abstract] [Full Text] [Related]

  • 12. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial.
    Sigrist M, Tang M, Beaulieu M, Espino-Hernandez G, Er L, Djurdjev O, Levin A.
    Nephrol Dial Transplant; 2013 Jan; 28(1):161-9. PubMed ID: 23024219
    [Abstract] [Full Text] [Related]

  • 13. [Information about phosphorus additives and nutritional counseling].
    Kido S, Nomura K, Sasaki S, Shiozaki Y, Segawa H, Tatsumi S.
    Clin Calcium; 2012 Oct; 22(10):1583-91. PubMed ID: 23023640
    [Abstract] [Full Text] [Related]

  • 14. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake.
    Uribarri J.
    Semin Dial; 2007 Oct; 20(4):295-301. PubMed ID: 17635818
    [Abstract] [Full Text] [Related]

  • 15. Phosphate binders in moderate chronic kidney disease: where do we stand?
    Bellasi A, Cozzolino M, Adragao T, Di Iorio B, Russo D.
    J Nephrol; 2013 Oct; 26(6):993-1000. PubMed ID: 23543481
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease].
    Mukhin NA, Milovanov YS, Kozlovskaya LV, Dobrosmyslov IA, Milovanova LY.
    Ter Arkh; 2016 Oct; 88(4):41-45. PubMed ID: 27070162
    [Abstract] [Full Text] [Related]

  • 19. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
    Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB.
    Kidney Int; 2003 Dec; 64(6):2272-9. PubMed ID: 14633152
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA, Shepler BM.
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.